Drugs / MVA LS2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03203421 Comparator | Jul → Dec 2017 | malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA LS2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03203421 ↗ |
| Modality | Vaccine | “the candidate malaria vaccines ChAdOx1 LS2 and MVA LS2” NCT03203421 ↗ |